 Cortexyme, a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimers and other degenerative diseases, today announced new preclinical data demonstrating the role of the bacterium P. gingivalis in Alzheimers disease AD and cardiovascular disease, providing a potential explanation for why the two diseases often occur together. Cortexyme also provided data demonstrating the therapeutic potential of its lead compound, atuzaginstat COR388, in treating both diseases. This data, along with two other poster presentations on atuzaginstat, are being presented by Cortexyme at the Alzheimers Association International Conference 2020 AAIC, which is taking place virtually from July 27-31. 